Skip to main content



) --




) hit a new 52-week low Wednesday as it is currently trading at $9.14, below its previous 52-week low of $9.22 with 3.5 million shares traded as of two p.m. ET. Average volume has been 6.3 million shares over the past 30 days.

Dendreon has a market cap of $1.5 billion and is part of the

health care

sector and


industry. Shares are down 70.9% year to date as of the close of trading on Tuesday.

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. The company offers active cellular immunotherapy and small molecule product candidates to treat various cancers.

  • Practice your DNDN trading strategies and win cash in our stock game.

TheStreet Ratings rates Dendreon as a


. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and generally weak debt management. You can view the full

Dendreon Ratings Report


See all

52-week low stocks

or get investment ideas from our

investment research center